Clinical Trial

Prevention of Metabolic Acidosis in Preterm Neonates by Replacing Sodium Chloride With Sodium Acetate in Parenteral Nutrition

Study acronym: PROTECT
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated May 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if the addition of sodium acetate in neonatal PN works to prevent and treat metabolic acidosis and associated comorbidities in preterm neonates. It will also teach about the optimal doses of sodium acetate in PN. The main questions it aims to answer are: Is the incidence of metabolic acidosis reduced in preterm neonates who received daily Sodium acetate in PN therapy (treatment) during the initial weeks of life compared with individuals who received sodium chloride in PN (standard)? Is the rate of neonatal comorbidities reduced in preterm neonates who received daily Sodium acetate in PN therapy (treatment) during the initial weeks of life compared with individuals who received sodium chloride in PN (standard)? What are the optimal neonatal dosing recommendations/guidelines of sodium acetate in daily PN, which are required to prevent/treat metabolic acidosis in the early life of preterm neonates? Researchers will compare Sodium acetate in PN therapy to sodium chloride in PN to see if Sodium acetate works to prevent and treat metabolic acidosis and associated comorbidities. Included Participants: All the neonates were admitted to the NICU of AKUH and received PN during 28 days of their lives. Participants will receive sodium acetate or sodium chloride Written informed consent was obtained by parents/legal representatives (according to local regulations) before the initiation of PN. Gestational age \< 33 weeks Included in the study before 72 hours of life
Trial Details
NCT Number NCT06545565
Lead Sponsor Aga Khan University Hospital, Pakistan
Conditions Metabolic Acidosis, Neonatal Disease, Neonatal Complication
Enrollment 200 participants
Start Date 2024-07-10
Primary Completion 2025-05-10 (estimated)
Study Completion 2025-05-10 (estimated)
Updated on ClinicalTrials.gov 2024-08-09